

Yana Pikman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4950396/publications.pdf>

Version: 2024-02-01

46
papers

3,503
citations

430754

18
h-index

330025

37
g-index

48
all docs

48
docs citations

48
times ranked

4213
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy. <i>Leukemia</i> , 2022, 36, 348-360.	3.3	23
2	The menin-MLL1 interaction is a molecular dependency in <i>NUP98</i> -rearranged AML. <i>Blood</i> , 2022, 139, 894-906.	0.6	42
3	SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma. <i>Blood</i> , 2022, 139, 538-553.	0.6	27
4	Rapid next-generation sequencing aids in diagnosis of transient abnormal myelopoiesis in a phenotypically normal newborn. <i>Blood Advances</i> , 2022, 6, 2893-2896.	2.5	2
5	Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts. <i>Cancer Discovery</i> , 2022, 12, 1760-1781.	7.7	15
6	Hypoxic, glycolytic metabolism is a vulnerability of B-acute lymphoblastic leukemia-initiating cells. <i>Cell Reports</i> , 2022, 39, 110752.	2.9	5
7	IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia. <i>Nature Cancer</i> , 2022, 3, 595-613.	5.7	16
8	Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05001 and 11001. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28719.	0.8	26
9	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. <i>Cancer Discovery</i> , 2021, 11, 1424-1439.	7.7	16
10	Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	29
11	Targeting the Ras pathway in pediatric hematologic malignancies. <i>Current Opinion in Pediatrics</i> , 2021, 33, 49-58.	1.0	5
12	Alisertib Synergistically Strengthens the Anti-Leukemia Activity of Venetoclax in <i>TCF3-Hlf</i> B-ALL. <i>Blood</i> , 2021, 138, 705-705.	0.6	0
13	Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2020, 10, 214-231.	7.7	27
14	The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies. <i>Cancer Discovery</i> , 2020, 10, 1894-1911.	7.7	13
15	Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 1265-1269.	2.5	5
16	3126 “ SINGLE CELL SEQUENCING OF MLL-REARRANGED LEUKEMIA REVEALS MECHANISMS OF LEUKEMIA INITIATING CELL PLASTICITY. <i>Experimental Hematology</i> , 2020, 88, S77.	0.2	0
17	The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies. <i>Blood</i> , 2019, 134, 877-877.	0.6	1
18	Exploiting an Asp-Glu “switch” in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	69

#	ARTICLE	IF	CITATIONS
19	Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27062.	0.8	48
20	Targeted therapy for fusion-driven high-risk acute leukemia. <i>Blood</i> , 2018, 132, 1241-1247.	0.6	22
21	Resistance Mechanisms to SYK Inhibition in AML. <i>Blood</i> , 2018, 132, 2638-2638.	0.6	1
22	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium. <i>Blood</i> , 2018, 132, 261-261.	0.6	3
23	The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. <i>Nature Medicine</i> , 2017, 23, 301-313.	15.2	79
24	Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 1012-1024.	3.2	88
25	Vcp-Regulated Homologous Recombination Represents a New Druggable Vulnerability in Acute Myeloid Leukemia. <i>Blood</i> , 2017, 130, 880-880.	0.6	0
26	A Prospective Cohort Quality Improvement Study to Reduce the Time to Antibiotics for New Fever in Neutropenic Pediatric Oncology Inpatients. <i>Pediatric Blood and Cancer</i> , 2016, 63, 112-117.	0.8	10
27	Targeting MTHFD2 in acute myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2016, 213, 1285-1306.	4.2	118
28	Targeting MTHFD2 in acute myeloid leukemia. <i>Journal of Cell Biology</i> , 2016, 214, 2141OIA135.	2.3	0
29	Targeting the Creatine Kinase Pathway in EVI1-Positive Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 523-523.	0.6	0
30	Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 2488-2488.	0.6	1
31	Phase Ib Trial of the mTOR Inhibitor Everolimus Given in Combination with Multiagent Chemotherapy in Relapsed Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 3765-3765.	0.6	3
32	Targeting MTHFD2 in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 443-443.	0.6	2
33	Identification of CKMT1B As a New Target in EVI1-Positive AML. <i>Blood</i> , 2015, 126, 3674-3674.	0.6	0
34	SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2014, 25, 226-242.	7.7	126
35	Pulmonary Hypertension Associated With Scurvy and Vitamin Deficiencies in an Autistic Child. <i>Pediatrics</i> , 2013, 132, e1699-e1703.	1.0	49
36	Targeting Folate Metabolism In Acute Myelogenous Leukemia. <i>Blood</i> , 2013, 122, 3798-3798.	0.6	1

#	ARTICLE	IF	CITATIONS
37	The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. <i>Journal of Clinical Investigation</i> , 2009, 119, 852-64.	3.9	80
38	Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray. <i>Experimental Hematology</i> , 2008, 36, 1471-1479.	0.2	44
39	The CDK-Activating Kinase (CAK) Csk1 Is Required for Normal Levels of Homologous Recombination and Resistance to DNA Damage in Fission Yeast. <i>PLoS ONE</i> , 2008, 3, e1492.	1.1	9
40	OTT-MAL Activates the Notch Signaling Transcription Factor RBPJ and Cooperates with Mutant MPL to Induce Acute Megakaryoblastic Leukemia. <i>Blood</i> , 2008, 112, 508-508.	0.6	0
41	Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders. <i>Current Opinion in Oncology</i> , 2007, 19, 628-634.	1.1	8
42	Peters Anomaly in Association with Multiple Midline Anomalies and a Familial Chromosome 4 Inversion. <i>Ophthalmic Genetics</i> , 2006, 27, 63-65.	0.5	14
43	MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. <i>Blood</i> , 2006, 108, 3472-3476.	0.6	963
44	MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia. <i>PLoS Medicine</i> , 2006, 3, e270.	3.9	1,222
45	Genetic Profiling of Myeloproliferative Disorders by Single Nucleotide Polymorphism Oligonucleotide Microarray.. <i>Blood</i> , 2006, 108, 2688-2688.	0.6	0
46	Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 18962-18967.	3.3	288